Compare MRTN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRTN | ESPR |
|---|---|---|
| Founded | 1946 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.3M | 898.5M |
| IPO Year | 1986 | 2013 |
| Metric | MRTN | ESPR |
|---|---|---|
| Price | $13.65 | $3.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $19.00 | $6.67 |
| AVG Volume (30 Days) | 1.1M | ★ 5.8M |
| Earning Date | 01-27-2026 | 03-03-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $883,652,000.00 | $303,802,000.00 |
| Revenue This Year | $2.16 | $27.49 |
| Revenue Next Year | $7.12 | N/A |
| P/E Ratio | $64.90 | ★ N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $9.35 | $0.69 |
| 52 Week High | $15.50 | $4.18 |
| Indicator | MRTN | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 68.39 | 41.79 |
| Support Level | $12.22 | $3.34 |
| Resistance Level | $14.02 | $3.64 |
| Average True Range (ATR) | 0.50 | 0.20 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 81.23 | 42.31 |
Marten Transport Ltd is a temperature-sensitive truckload carrier in the United States. The company specializes in transporting and distributing food and other consumer packaged goods that require a temperature-controlled or insulated environment. It operates through four segments: Truckload, Dedicated, Intermodal, and Brokerage, generating the majority of its revenue from the Truckload segment. The Truckload segment offers a mix of regional short-haul and medium- to long-haul full-load transportation services.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.